Šalis: Airija
kalba: anglų
Šaltinis: HPRA (Health Products Regulatory Authority)
FLUVASTATIN
McDermott Laboratories Ltd t/a Gerard Laboratories
40 Milligram
Capsules Hard
2009-10-09
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Statease 40 mg hard capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains fluvastatin 40 mg as fluvastatin sodium For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Capsules, hard Statease 40 mg capsules are No. 1 hard gelatine, red capsules, with ‘FL 40’ printed on the cap and ‘G’ printed on the body, containing a white to pale yellow or brownish-pale yellow or reddish-pale yellow powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Dyslipidaemia Treatment of adults with primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate. Secondary prevention in coronary heart disease Secondary prevention of major adverse cardiac events in adults with coronary heart disease after percutaneous coronary interventions (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Adults_ Dyslipidaemia Prior to initiating treatment with fluvastatin, patients should be placed on a standard cholesterol lowering diet, which should be continued during treatment. Starting and maintenance doses should be individualized according to the baseline LDL-C levels and the treatment goal to be accomplished. The recommended dosing range is 20 to 80 mg/day. For patients requiring LDL-C reduction to a goal of < 25% a starting dose of 20 mg may be used as one capsule in the evening. For patients requiring LDL-C reduction to a goal of ≥25%, the recommended starting dose is 40 mg as one capsule in the evening. The dose may be uptitrated to one 40 mg capsule given twice daily (one in the Perskaitykite visą dokumentą